<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35095044</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1882-0654</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month><Day>19</Day></PubDate></JournalIssue><Title>Rinsho shinkeigaku = Clinical neurology</Title><ISOAbbreviation>Rinsho Shinkeigaku</ISOAbbreviation></Journal><ArticleTitle>[Survey of patients with advanced-stage Okinawa-type neurogenic muscular atrophy (hereditary motor and sensory neuropathy with proximal dominant involvement: HMSN-P)].</ArticleTitle><Pagination><StartPage>152</StartPage><EndPage>156</EndPage><MedlinePgn>152-156</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5692/clinicalneurol.cn-001576</ELocationID><Abstract><AbstractText>We conducted a survey of 16 Japanese patients (9 males, 7 females) aged 48-70 years in the advanced-stage Okinawa-type neurogenic muscular atrophy (i.e. hereditary motor and sensory neuropathy with proximal dominant involvement: HMSN-P) by a questionnaire asking the patients' disease name notification, acceptance, and expectations for treatment. In amyotrophic lateral sclerosis (ALS), since symptoms such as four-limb motor weakness and respiratory disorder are serious, patients are notified of the disease name at each progression stage. Individuals with HMSN-P exhibit ALS-like severe motor paralysis, but HMSN-P shows autosomal dominant inheritance, and progresses slowly (over &gt;30 years). Many of the present patients who had one parent with the disease were able to predict what their diagnosis would be. However, several patients stated that they could not sleep for several months due to the shock of the diagnosis and their concern about how to explain to their children that the disease is hereditary. All patients in the advanced stage of HMSN-P progress to severe proximal dominant quadriplegia and ultimately need auxiliary tools such as a wheelchair. New developments toward a specific HMSN-P treatment are expected, with methods such as nucleic acid medicine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Taniguchi</LastName><ForeName>Masahiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgery, St. Mary's Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yorishima</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, St. Mary's Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoji</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, St. Mary's Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ide</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Healthcare-Center, St. Mary's Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumura</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Rehabilitation Unit, St. Mary's Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunisaki</LastName><ForeName>Keisuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Rehabilitation Unit, St. Mary's Hospital.</Affiliation></AffiliationInfo></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Rinsho Shinkeigaku</MedlineTA><NlmUniqueID>0417466</NlmUniqueID><ISSNLinking>0009-918X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015417" MajorTopicYN="Y">Hereditary Sensory and Motor Neuropathy</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018908" MajorTopicYN="N">Muscle Weakness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009133" MajorTopicYN="N">Muscular Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Okinawa-type neurogenic muscular atrophy</Keyword><Keyword MajorTopicYN="N">disease name notification</Keyword><Keyword MajorTopicYN="N">hereditary motor and sensory neuropathy with proximal involvement</Keyword><Keyword MajorTopicYN="N">questionnaire survey</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>31</Day><Hour>5</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35095044</ArticleId><ArticleId IdType="doi">10.5692/clinicalneurol.cn-001576</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>